Intellia Therapeutics Inc

NASDAQ:NTLA   3:59:50 PM EDT
62.71
+1.79 (+2.94%)
Products

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation For NTLA-2002, An Investigational CRISPR Therapy For The Treatment Of Hereditary Angioedema

Published: 09/01/2022 20:21 GMT
Intellia Therapeutics Inc (NTLA) - Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for Ntla-2002, an Investigational Crispr Therapy for the Treatment of Hereditary Angioedema.
Intellia Therapeutics Inc - Ntla-2002, is Currently Being Evaluated in a Phase 1/2 Study.